# Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

> **NCT05466890** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Palatin Technologies, Inc** · enrollment: 16 (estimated)

## Conditions studied

- Ulcerative Colitis
- Ulcerative Colitis Acute
- Ulcerative
- Ulcerative Colitis Flare

## Interventions

- **DRUG:** PL8177 Placebo
- **DRUG:** PL8177

## Key facts

- **NCT ID:** NCT05466890
- **Lead sponsor:** Palatin Technologies, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-15
- **Primary completion:** 2025-02-10
- **Final completion:** 2025-03-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05466890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05466890, "Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05466890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*